EN DE
Watch Infant Bacterial Therapeutics AB (publ) for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Infant Bacterial Therapeutics AB (publ) (IBT-B) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Infant Bacterial Therapeutics AB (publ) stock SEK 38.88, price SEK 67.50, that is 42.4% below the price, quality 62 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0008015259

IB Infant Bacterial Therapeutics AB (publ) logo Thin data Nov 17, 2026

Infant Bacterial Therapeutics AB (publ)

IBT-B · ST

Far too expensive (fair value 42% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Quality 62/100 
Rising price (uptrend) 
Revenue last quarter 62% below a year ago. 
Fair value kr 38.88 · Strongly overvalued 
Weak Growth (revenue YoY −94.8 %/yr in SEK) 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Infant Bacterial Therapeutics AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 124.50 kr 31.60 Fair Value kr 38.88 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range kr 31.60 – kr 124.50 · fair‑value band kr 29.16 – kr 48.59 · the kr 67.50 price screens above the kr 38.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Infant Bacterial Therapeutics AB (publ) in your weekly email

Every Wednesday you see whether Infant Bacterial Therapeutics AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden.

Show moreShow less

The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants.

It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.

In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections.

The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.

Stock analysis

Infant Bacterial Therapeutics AB (publ) (IBT-B) currently trades at kr 67.50, while our estimate is kr 38.88, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 29.16 (bear) to kr 48.59 (bull), the price of kr 67.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Infant Bacterial Therapeutics AB (publ) reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −65.2M SEK in FY2025.

Key figures

Market cap 909M SEK (≈ $90.0M) Micro · EPS (TTM) kr −6.05 · Return on equity −87.4% · Return on assets (EBIT) −33.8% (5-year average) · Revenue (TTM) −1.0K SEK · Revenue growth (YoY) −61.5% · EPS growth (YoY) −61.7% · Free cash flow −72.3M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 55% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, IBT-B screens richer than that median.

Fair Value

Bear kr 29.16 Fair Value kr 38.88 Bull kr 48.59
Price kr 67.50 · Downside -42.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 62/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 70
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 54
How calm the share price moves, does not count
Price momentum 63
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 56
Distance to the 52-week high, does not count
New shares 67
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−94.8%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15,185.3% (2017) → −3,497,550.0% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IBT-B screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Infant Bacterial Therapeutics AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 62 · Top 25%
Fair Value upside −42.4% · Bottom 25%
Profitability
Return on assets −40.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) −61.5% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.85× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs IBT-B
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs IBT-B
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs IBT-B
argenx SE ARGX $950.95 $908.40 −4% vs IBT-B
CSL Limited CSL A$199.55 A$186.49 −7% vs IBT-B
Moderna, Inc MRNA $215.27 $135.64 −37% vs IBT-B
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs IBT-B
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs IBT-B
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs IBT-B
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs IBT-B

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Infant Bacterial Therapeutics AB (publ): fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Infant Bacterial Therapeutics AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/IBT-B

Frequently asked questions

Is Infant Bacterial Therapeutics AB (publ) (IBT-B) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is kr 38.88 versus a price of kr 67.50, about 42% lower (overvalued).
What is the fair value of IBT-B?
Our estimate for Infant Bacterial Therapeutics AB (publ) is kr 38.88 (as of Nov 17, 2026), built from audited fundamentals. The current price: kr 67.50.
What is the quality score of IBT-B?
Infant Bacterial Therapeutics AB (publ) has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Our calculated price target is the estimate of kr 38.88 (as of Nov 17, 2026). Cautious scenario kr 29.16, optimistic scenario kr 48.59. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Infant Bacterial Therapeutics AB (publ) stock forecast for 2026?
Our estimate puts fair value at kr 38.88, about 42% lower versus a price of kr 67.50 (overvalued). Cautious scenario kr 29.16, optimistic scenario kr 48.59. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Infant Bacterial Therapeutics AB (publ) it is kr 38.88 per share (as of Nov 17, 2026), against a price of kr 67.50.
Is Infant Bacterial Therapeutics AB (publ) stock overvalued or undervalued in 2026?
As of Nov 17, 2026, IBT-B trades above its calculated fair value: price kr 67.50, fair value kr 38.88, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IBT-B?
No. The price is what the market pays today (kr 67.50); the fair value is what the company's own numbers justify (kr 38.88). For Infant Bacterial Therapeutics AB (publ) the two are kr 28.62 per share apart. That gap is exactly why we show both numbers side by side.
How much is Infant Bacterial Therapeutics AB (publ) worth?
The market values Infant Bacterial Therapeutics AB (publ) at about 909M SEK (market capitalisation, as of Nov 17, 2026). Per share that is kr 67.50; our models calculate a fair value of kr 38.88 per share.
What do the bullish and bearish scenarios say about IBT-B?
Our models span a range for Infant Bacterial Therapeutics AB (publ): cautious scenario kr 29.16, base kr 38.88, optimistic kr 48.59 per share (as of Nov 17, 2026, price kr 67.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Balance-sheet figures for Infant Bacterial Therapeutics AB (publ) (as of Nov 17, 2026): return on equity −87.4%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is IBT-B from its 52-week high?
Infant Bacterial Therapeutics AB (publ) trades at kr 67.50, about 18% below its 52-week high of kr 82.80 and 55% above the low of kr 43.45 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of kr 38.88 is for.
Which stocks are comparable to Infant Bacterial Therapeutics AB (publ)?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Infant Bacterial Therapeutics AB (publ) stock attractive at the current price?
The data as of Nov 17, 2026: price kr 67.50, calculated fair value kr 38.88 (−42%), Quality Score 62/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Infant Bacterial Therapeutics AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
The closing price on Nov 17, 2026 was kr 67.50. Our estimate is kr 38.88, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Infant Bacterial Therapeutics AB (publ) right now?
The price sits above even our optimistic bull case (kr 48.59). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Infant Bacterial Therapeutics AB (publ)

How large is the market capitalisation of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
The market capitalisation of Infant Bacterial Therapeutics AB (publ) is 909M SEK (≈ $90.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Earnings per share at Infant Bacterial Therapeutics AB (publ) are kr −6.05. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
The return on equity (ROE) of Infant Bacterial Therapeutics AB (publ) is −87.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Infant Bacterial Therapeutics AB (publ) (IBT-B)?
On an EBIT basis the return on assets of Infant Bacterial Therapeutics AB (publ) is −33.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much revenue does Infant Bacterial Therapeutics AB (publ) (IBT-B) generate?
Infant Bacterial Therapeutics AB (publ) generates revenue of −1.0K SEK (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Revenue at Infant Bacterial Therapeutics AB (publ) is down 61.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Infant Bacterial Therapeutics AB (publ) (IBT-B)?
Earnings per share at Infant Bacterial Therapeutics AB (publ) are down 61.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Infant Bacterial Therapeutics AB (publ) (IBT-B) generate?
The free cash flow of Infant Bacterial Therapeutics AB (publ) is −72.3M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Infant Bacterial Therapeutics AB (publ) (IBT-B) hold?
Infant Bacterial Therapeutics AB (publ) holds more cash than debt, 144M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Infant Bacterial Therapeutics AB (publ) in the live analysis

One click puts Infant Bacterial Therapeutics AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.